PHAXIAM Therapeutics S.A.
PHAXIAM Therapeutics S.A. (PHXM) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
phxm · pe ratio · data through Dec 31, 2023
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for PHAXIAM Therapeutics S.A. (PHXM) measures how much investors pay for each dollar of the company's trailing earnings. PHXM's current PE ratio of N/A is calculated by dividing its stock price of $3.10 by its TTM earnings per share of -$5.00.
Source: FMP · /ratios-ttm · /analyst-estimates · 2023-12-31
PE Ratio History
2010 – 2023 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
PHAXIAM Therapeutics S.A.You PHXM | $20M | N/A | — | -$5.00 |
 AlphaTON Capital Corp. ATON | $1M | N/A | — | -$5.72 |
 COSCIENS Biopharma Inc. CSCI | $9M | N/A | — | -$5.93 |
 Dominari Holdings Inc. DOMH | $51M | N/A | — | -$1.57 |
 Elevation Oncology, Inc. ELEV | $22M | N/A | — | -$0.78 |
 Kineta, Inc. KA | $7M | N/A | — | -$1.42 |
 MEI Pharma, Inc. MEIP | $20M | N/A | — | -$2.39 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2023-12-31Latest FY2023 | — | $-4.62 | — | |
2022-12-31 FY2022 | — | $-0.07 | — | |
2021-12-31 FY2021 | — | $-22.71 | — | |
2020-12-31 FY2020 | — | $-36.54 | — | |
2019-12-31 FY2019 | — | $-32.28 | — | |
2018-12-31 FY2018 | — | $-19.69 | — | |
2017-12-31 FY2017 | — | $-27.26 | — | |
2016-12-31 FY2016 | — | $-2.74 | — | |
2015-12-31 FY2015 | — | $-2.16 | — | |
2014-12-31 FY2014 | — | $-1.51 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for PHAXIAM Therapeutics S.A. (PHXM) measures how much investors pay for each dollar of the company's trailing earnings. PHXM's current PE ratio of N/A is calculated by dividing its stock price of $3.10 by its TTM earnings per share of -$5.00.
Frequently asked questions
PHXM pe ratio · 6 questionsPHXM's current PE ratio is N/A as of 2026-06-13, based on a stock price of $3.10 and TTM EPS of -$5.00. Data sourced from Financial Modeling Prep via PHXM's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · PHAXIAM Therapeutics S.A. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-13